EUVIMEDEUVIMED entdecken
Open Access

High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi

Rizine R Mzikamanda iD, Loviisa Mulanje iD, Casey L McAtee iD, Apatsa Matatiyo, Zoe Mwale, Grace Chirwa, Watipaso Wanda, Atupele Miranda Mpasa iD, Stella Wachepa iD, Minke H W Huibers iD, Steve Martin iD, Tamiwe Tomoka iD und 9 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Rizine R Mzikamanda und 20 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology-Oncology, Kamuzu Central Hospital, Lilongwe, Malawi. Hauptthemen laut MEDLINE: Methotrexate, Lymphoma, B-Cell, Antimetabolites, Antineoplastic. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Excellent survival for advanced (stages II with high lactate dehydrogenase, III, and IV) pediatric mature B-cell non-Hodgkin lymphoma (MB-NHL) has been achieved with intensive regimens, but adoption in sub-Saharan Africa is limited by inadequate supportive care. We provide real-world data on treating advanced MB-NHL with high-dose methotrexate (HD-MTX; ≥1,000 mg/m 2 /cycle) where real-time serum MTX monitoring is unavailable. METHODS We identified two cohorts—a retrospective (January 2017-December 2020) cohort treated with 1,000 or 3,000 mg/m 2 /cycle of HD-MTX and a prospective (July 2022-July 2023) cohort—with a modified LMB96 protocol containing 3,000 mg/m 2 /cycle of HD-MTX. All doses of HD-MTX were given over 3 hours. Estimates of 12-month event-free survival (EFS) and overall survival (OS) were calculated with abandonment as an event. Clinical toxicity data were available for the prospective cohort. RESULTS The retrospective cohort had 108 patients who received HD-MTX 1,000 mg/m 2 (n = 98, 91%) or 3,000 mg/m 2 per cycle. The 12-month EFS and OS were 39% (95% CI, 30 to 50) and 54% (95% CI, 44 to 64), respectively. HD-MTX at 3,000 mg/m 2 had superior EFS: 69% (95% CI, 49 to 96) versus 33% (95% CI, 24 to 46), P = .004. The prospective cohort had 38 patients. Two ≥grade 3 mucositis, one acute kidney injury, and three treatment-related deaths (8%) occurred. Seven (18%) abandoned treatment. With a median follow-up of 14.5 months, 12-month EFS and OS were 45% (95% CI, 32 to 65) and 59% (95% CI, 45 to 79), respectively. Most relapses were stage IV: EFS 20% versus 51% (non–stage IV; P = .057). Severe malnutrition was associated with OS of 33% versus 58% (normal) or 76% (moderate; P = .055). CONCLUSION HD-MTX dosed at 3,000 mg/m 2 /cycle is feasible in low-resource settings where routine MTX monitoring is unavailable. Stage IV disease and severe malnutrition may contribute to poorer outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateLymphoma, B-CellAntimetabolites, AntineoplasticHumansMalawiFemaleMaleChildRetrospective StudiesAdolescentChild, PreschoolProspective StudiesDrug MonitoringResource-Limited Settings

Substanzen

MethotrexateAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Pediatric Hematology-Oncology, Kamuzu Central Hospital, Lilongwe, Malawi.
  • Baylor College of Medicine Children's Foundation-Malawi, Lilongwe, Malawi.
  • Department of Epidemiological Methods and Etiological Research, Leibniz Institute of Prevention Research and Epidemiology, Bremen, Germany.
  • Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Global HOPE, Texas Children's Hospital, Houston, TX.
  • University of North Carolina Project Malawi, Lilongwe, Malawi.

ORCID-Profile: Rizine R Mzikamanda, Loviisa Mulanje, Casey L McAtee, Atupele Miranda Mpasa, Stella Wachepa, Minke H W Huibers, Steve Martin, Tamiwe Tomoka, Maurice Mulenga, Yuri Fedoriw, Gugulethu Mapurisa, Julie M Gastier Foster, Nader El-Mallawany, Carl E Allen, Nmazuo Ozuah

Förderung

  • NCI NIH HHS

Zitieren

APA

Mzikamanda, R. R., Mulanje, L., McAtee, C. L., Matatiyo, A., Mwale, Z., Chirwa, G., Wanda, W., Mpasa, A. M., Wachepa, S., Huibers, M. H. W., Martin, S., Tomoka, T., Mulenga, M., Fedoriw, Y., Mapurisa, G., Gastier Foster, J. M., El-Mallawany, N., Westmoreland, K. D., Wasswa, P., …, & Ozuah, N. (2025). High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi. JCO Global Oncology. https://doi.org/10.1200/go-24-00591

Vancouver

Mzikamanda RR, Mulanje L, McAtee CL, Matatiyo A, Mwale Z, Chirwa G, et al. High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi. JCO Global Oncology. 2025. doi:10.1200/go-24-00591

BibTeX
@article{Mzikamanda2025,
  author = {Mzikamanda, Rizine R and Mulanje, Loviisa and McAtee, Casey L and Matatiyo, Apatsa and Mwale, Zoe and Chirwa, Grace and Wanda, Watipaso and Mpasa, Atupele Miranda and Wachepa, Stella and Huibers, Minke H W and Martin, Steve and Tomoka, Tamiwe and Mulenga, Maurice and Fedoriw, Yuri and Mapurisa, Gugulethu and Gastier Foster, Julie M and El-Mallawany, Nader and Westmoreland, Katherine D and Wasswa, Peter and Allen, Carl E and Ozuah, Nmazuo},
  title = {High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00591}
}
Kostenlos starten →